2026. Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III RenalCell Carcinoma. Journal of Kidney Cancer. 13, 2 (Jun. 2026), 21–28. DOI:https://doi.org/10.15586/jkcvhl.v13i2.455.